Humacyte vs Korsana Biosciences
Humacyte and Korsana Biosciences are similar in size: $2.0m and $2.1m of revenue in their latest fiscal years. Korsana Biosciences kept more of each dollar of sales as profit: a net margin of -170.1% against -2003.6%. Korsana Biosciences carries less debt relative to equity (0.0% against 1140.0%).
| Latest fiscal year | HumacyteHUMA, 2025 | Korsana BiosciencesKRSA, 2025 |
|---|---|---|
| Revenue | $2.0m | $2.1m |
| Revenue growth | — | 3.7% |
| Net income | −$40.8m | −$3.5m |
| Operating margin | -5306.0% | -239.8% |
| Net margin | -2003.6% | -170.1% |
| Return on equity | — | -39.3% |
| Free cash flow | −$106m | −$3.3m |
| Cash | $50.5m | $3.2m |
| Total debt | $35.4m | $0 |
| Debt to equity | 1140.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 184 | — |
| Market value | $120m | $138m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 5 buys, 2 sales | 0 buys, 0 sales |